CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
自然选择的 CD7 靶向 CAR-T 桥接 allo-HSCT 治疗难治性急性髓系白血病：病例报告与综述
英文原题：Naturally selected CD7-directed CAR-T bridging allo-HSCT in refractory acute myeloid leukemia: a case report and review.
查看英文原题
Naturally selected CD7-directed CAR-T bridging allo-HSCT in refractory acute myeloid leukemia: a case report and review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
复发/难治性急性髓系白血病（R/R-AML）预后不良。约30%的AML患者白血病细胞表达CD7，而正常髓系细胞不表达。因此，CD7可能成为R/R-AML免疫治疗的潜在靶点。基于异种移植模型，自然筛选的靶向CD7CAR-T 细胞对AML显示出良好效果。我们报告一例患者经自然筛选的CD7 CAR-T 治疗后获得完全缓解但血液学恢复不完全的R/R-AML病例。CAR-T 治疗后早期进行异基因造血干细胞移植（allo-HSCT）作为巩固治疗；截至目前，患者已无病生存期12个月。我们的结果证实，自然筛选的CD7 CAR-T 治疗后进行异基因造血干细胞移植，可能成为CD7阳性R/R-AML患者的一种潜在治疗方案。
展开英文摘要原文
Relapsed/refractory acute myeloid leukemia (R/R-AML) has a poor prognosis. CD7 is expressed in leukemic cells in 30% of patients with AML but not in normal myeloid cells.
Therefore, it can be a potential target for immunotherapy in patients with R/R-AML. Naturally selected CD7-directed chimeric antigen receptor T cells (CAR-T) have promising effects against AML based on xenotransplantation models.
We report a R/R-AML case that achieved complete remission with incomplete hematologic recovery with naturally selected CD7 CAR-T therapy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) as consolidation early after CAR T therapy, the patient experienced 12 months of disease-free survival to date.
Our results confirmed that allogeneic hematopoietic stem cell transplantation after naturally selected CD7 CAR-T therapy can be a potential treatment for patients with CD7-positive R/R-AML.
论文信息
- 作者
- Liu X、Xu Z、Li S、Zhang X、Li J、Li H、Wang F
- 单位
- Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang, Hebei, China.China
- 文献类型
- 病例报告 · 综述
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39469704 · DOI 10.3389/fimmu.2024.1461908
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →